CVRx ended the quarter with 56 U.S. sales territories, unchanged from the first quarter. In regions with experienced leadership and limited turnover, CVRx said it continued to see strong double-digit growth under its program-development selling strategy. CVRx plans instead to focus on improving productivity in existing territories and driving deeper adoption at active implanting centers. Separately, Hykes disclosed that CVRx received a civil investigative demand from the U.S. Department of Justice in May related to certain sales and marketing practices. About CVRx (NASDAQ:CVRX)CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease.